Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003

NEWS EXPRESS	January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:03:47 ON 29 JAN 2003

=> fil .search
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 11:04:30 ON 29 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:04:30 ON 29 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:04:30 ON 29 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 11:04:30 ON 29 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:04:30 ON 29 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s cardiovascul?
L1 1196311 CARDIOVASCUL?

<------User Break------>

SEARCH ENDED BY USER

=> s l1 and imaging(w)agent?
L2 1250 L1 AND IMAGING(W) AGENT?

=> s l2 and (radionuclide?)
L3 218 L2 AND (RADIONUCLIDE?)

=> s l3 and chelat?
L4 134 L3 AND CHELAT?

=> s l4 and (target?)
L5 117 L4 AND (TARGET?)

=> s l5 and plaque?
L6 50 L5 AND PLAQUE?

=> dup rem l6

```
PROCESSING COMPLETED FOR L6
L7            50 DUP REM L6 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 50 ANSWERS - CONTINUE? Y/(N):y
```

L7 ANSWER 1 OF 50 USPATFULL
ACCESSION NUMBER: 2003:26138 USPATFULL
TITLE: Vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas D., 56 Zion Hill Rd., Salem, NH, United States 03079
Barrett, John A., 46 Fox Run, Groton, MA, United States
01450
Carpenter, Jr., Alan P., 73 Cranberry Hill La., Carlisle, MA, United States 01741
Rajopadhye, Milind, 21 Honeysuckle Rd., Westford, MA, United States 01886

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511649	B1	20030128
APPLICATION INFO.:	US 2000-599364		20000621 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-465300, filed on 17 Dec 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112732P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Dolan, Peter L., Golian, Paul D.
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 9269
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a **targeting** moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L7 ANSWER 2 OF 50 USPATFULL
ACCESSION NUMBER: 2002:338201 USPATFULL
TITLE: WSX RECEPTOR AGONIST ANTIBODIES
INVENTOR(S): CARTER, PAUL J., SAN FRANCISCO, CA, UNITED STATES
CHIANG, NANCY Y., SAN FRANCISCO, CA, UNITED STATES
KIM, KYUNG JIN, LOS ALTOS, CA, UNITED STATES
MATTHEWS, WILLIAM, WOODSIDE, CA, UNITED STATES
RODRIGUES, MARIA L., SOUTH SAN FRANCISCO, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193571	A1	20021219
APPLICATION INFO.:	US 1997-779457	A1	19970107 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-667197, filed on 20 Jun 1996, PENDING Continuation-in-part of Ser. No. US 1996-585005, filed on 8 Jan 1996, ABANDONED		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GINGER R. DREGER, KNOBBE, MARTENS, OLSON & BEAR, LLP, 620 NEWPORT CNETER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 61 Drawing Page(s)
LINE COUNT: 6038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Agonist antibodies which bind to and activate the WSX receptor are described along with various uses for these antibodies. Preferred antibodies are those which display an IC50 in the KIRA ELISA bioassay of about 0.5 .mu.g/ml or less.

L7 ANSWER 3 OF 50 USPATFULL
ACCESSION NUMBER: 2002:321986 USPATFULL
TITLE: VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS
INVENTOR(S): HARRIS, THOMAS D., SALEM, NH, UNITED STATES
RAJOPADHYE, MILIND, WESTFORD, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002182147	A1	20021205
	US 6511648	B2	20030128
APPLICATION INFO.:	US 1999-465300	A1	19991217 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112732P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 7362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a **targeting** moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L7 ANSWER 4 OF 50 USPATFULL
ACCESSION NUMBER: 2002:294624 USPATFULL
TITLE: VEGFR-3 inhibitor materials and methods
INVENTOR(S): Alitalo, Kari, Helsinki, FINLAND
Koivunen, Erkki, Helsinki, FINLAND
Kubo, Hajime, Helsinki, FINLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164667	A1	20021107
APPLICATION INFO.:	US 2002-46922	A1	20020115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262476P	20010117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 3685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.

L7 ANSWER 5 OF 50 USPATFULL
ACCESSION NUMBER: 2002:287093 USPATFULL
TITLE: Novel **targeted** compositions for diagnostic and therapeutic use
INVENTOR(S): Unger, Evan C., Tucson, AZ, UNITED STATES
McCreery, Thomas P., Alexandria, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002159951	A1	20021031
APPLICATION INFO.:	US 2002-55772	A1	20020123 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-699679, filed on 30 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-496761, filed on 3 Feb 2000, PENDING Division of Ser. No. US 1997-851780, filed on 6 May 1997, GRANTED, Pat. No. US 6090800
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
NUMBER OF CLAIMS: 110
EXEMPLARY CLAIM: 1
LINE COUNT: 4629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel **targeted** compositions which may be used for diagnostic and therapeutic use. The compositions may comprise lipid, protein or polymer gas-filled vesicles which further comprise novel compounds of the general formula L-P-T, wherein L comprises a hydrophobic compound, P comprises a hydrophilic polymer, and T comprises a **targeting** ligand which **targets** tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The compositions can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

L7 ANSWER 6 OF 50 USPATFULL
ACCESSION NUMBER: 2002:234998 USPATFULL
TITLE: Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable **plaque**
INVENTOR(S): Edwards, Scott, Burlington, MA, UNITED STATES
Liu, Shuang, Chelmsford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127181	A1	20020912
APPLICATION INFO.:	US 2002-80974	A1	20020222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270954P	20010223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 2386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various **cardiovascular** diseases including but not limited to atherosclerosis, vulnerable **plaque**, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.

L7 ANSWER 7 OF 50 USPATFULL
ACCESSION NUMBER: 2002:227618 USPATFULL
TITLE: Ascorbic acid analogs for metalloradiopharmaceuticals
INVENTOR(S): Liu, Shuang, Chelmsford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122769	A1	20020905
APPLICATION INFO.:	US 2002-81258	A1	20020222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271389P	20010226 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
LINE COUNT: 1882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of ascorbic acid analogs as buffering reagents and **chelating** agents for the preparation of metalloradiopharmaceuticals. Also, invention relates to the use of ascorbic acid as a buffering reagent, a **chelating** agent, and a stabilizer for the preparation and stabilization of radiopharmaceuticals and processes for making and using the same.

L7 ANSWER 8 OF 50 USPATFULL
ACCESSION NUMBER: 2002:227617 USPATFULL
TITLE: Stable radiopharmaceutical compositions and methods for preparation thereof
INVENTOR(S): Liu, Shuang, Chelmsford, MA, UNITED STATES
Barrett, John A., Groton, MA, UNITED STATES
Carpenter, Alan P., JR., Carlisle, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122768	A1	20020905
APPLICATION INFO.:	US 2001-899629	A1	20010705 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-216396P	20000706 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 92
EXEMPLARY CLAIM: 1
LINE COUNT: 4115
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides stable radiopharmaceutical compositions including a therapeutic **radionuclide** and an effective stabilizing amount of an aromatic stabilizer (e.g., a polyhydroxylated aromatic compound, an aromatic amine, or a hydroxylated aromatic amine), alone or in combination with other antioxidants or stabilizers, to inhibit radiolytic degradation of radiopharmaceuticals. The present invention also provides improved radiopharmaceutical formulations by the use of an aromatic stabilizing agent (e.g., a polyhydroxylated aromatic compound, an aromatic amines, or a hydroxylated aromatic amine), and/or low temperature storage. The present invention also provides processes for making stable radiopharmaceutical compositions. The present invention also provides the use of the pharmaceutical compositions in medical therapy and/or medical diagnosis.

L7 ANSWER 9 OF 50 USPATFULL
ACCESSION NUMBER: 2002:220963 USPATFULL
TITLE: Methods of imaging and **targeting** vasculature
INVENTOR(S): Gale, Nicholas W., Tarrytown, NY, UNITED STATES
Yancopoulos, George D., Yorktown Heights, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119097	A1	20020829
APPLICATION INFO.:	US 2002-55842	A1	20020123 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264406P	20010126 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Linda O. Palladino, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for imaging and **targeting** tumor vasculature are provided. Specifically, the methods for imaging and **targeting** tumor vasculature relate to using ephrin-B2 to image developing tumor vasculature and to **target** therapeutic agents to developing tumor vasculature. Kits for imaging and **targeting** tumor vasculature are also provided. Also provided for are methods of delivering agents to vasculature.

L7 ANSWER 10 OF 50 USPATFULL
ACCESSION NUMBER: 2002:213736 USPATFULL
TITLE: Neutrokine-alpha and Neutrokine-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002115112	A1	20020822
APPLICATION INFO.:	US 2001-929493	A1	20010815 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-586288, filed on 2 Jun 2000, PATENTED Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)

L7 ANSWER 10 OF 50 USPATFULL (Continued)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 117
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 18178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind
Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic
methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

L7 ANSWER 11 OF 50 USPATFULL
ACCESSION NUMBER: 2002:198232 USPATFULL
TITLE: Simultaneous imaging of cardiac perfusion and a vitronectin receptor **targeted imaging agent**
INVENTOR(S): Carpenter,, Alan P., JR., Carlisle, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106325	A1	20020808
APPLICATION INFO.:	US 2001-995388	A1	20011127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	PH 2000-7201	20001127

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT,
P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
LINE COUNT: 6224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes a method of concurrent imaging in a mammal comprising:

a) administering to said mammal a vitronectin receptor **targeted imaging agent** and a perfusion **imaging agent**; and

b) concurrently detecting the vitronectin **target imaging agent** bound at the vitronectin receptor and the perfusion **imaging agent**; and

c) forming an image from the detection of said vitronectin receptor **targeted imaging agent** and said perfusion **imaging agent**.

L7 ANSWER 12 OF 50 USPATFULL
ACCESSION NUMBER: 2002:185242 USPATFULL
TITLE: New macrocyclic chelants useful for metallopharmaceuticals
INVENTOR(S): Liu, Shuang, Chelmsford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098149	A1	20020725
APPLICATION INFO.:	US 2001-33765	A1	20011227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-260500P	20010109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 1855
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Macrocyclic chelant are disclosed, as well as **chelates** of the chelants with metal ions to form radiopharmaceutical and radioactive, MRI and X-ray or CT imaging compounds and compositions. Therapeutic and imaging methods of use are also disclosed.

L7 ANSWER 13 OF 50 USPATFULL
ACCESSION NUMBER: 2002:178530 USPATFULL
TITLE: Polypodal chelants for metallopharmaceuticals
INVENTOR(S): Liu, Shuang, Chelmsford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094316	A1	20020718
APPLICATION INFO.:	US 2001-33769	A1	20011227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-260618P	20010109 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 110
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polypodal chelants are disclosed, as well as **chelates** of the chelants with metal ions to form radiopharmaceutical and radioactive, MRI and X-ray or CT imaging compounds and compositions. Therapeutic and imaging methods of use are also disclosed.

L7 ANSWER 14 OF 50 USPATFULL
ACCESSION NUMBER: 2002:126317 USPATFULL
TITLE: Human tumor necrosis factor delta and epsilon
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002064829	A1	20020530
APPLICATION INFO.:	US 2001-879919	A1	20010614 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar 1997, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-16812P	19960314 (60)
	US 2001-293499P	20010525 (60)
	US 2001-277978P	20010323 (60)
	US 2001-276248P	20010316 (60)
	US 2000-254875P	20001213 (60)
	US 2000-241952P	20001023 (60)
	US 2000-211537P	20000615 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 13531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

L7 ANSWER 15 OF 50 USPATFULL
ACCESSION NUMBER: 2002:119921 USPATFULL
TITLE: Vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas D., Salem, NH, UNITED STATES
Rajopadhye, Milind, Westford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061909	A1	20020523
APPLICATION INFO.:	US 2001-948390	A1	20010907 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-465300, filed on 17 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112732P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, Legal - Patents, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 7403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a **targeting** moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L7 ANSWER 16 OF 50 USPATFULL
ACCESSION NUMBER: 2002:92631 USPATFULL
TITLE: Cobalamin compounds useful as **cardiovascular** agents and as **imaging agents**
INVENTOR(S): Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049155	A1	20020425
APPLICATION INFO.:	US 2001-873142	A1	20010531 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208140P	20000531 (60)
	US 2001-267782P	20010209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 4521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides cobalamin derivatives linked to a **cardiovascular** agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a **cardiovascular** disease.

L7 ANSWER 17 OF 50 USPATFULL
ACCESSION NUMBER: 2002:78225 USPATFULL
TITLE: Vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas D., Salem, NH, UNITED STATES
Rajopadhye, Milind, Westford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002041878	A1	20020411
APPLICATION INFO.:	US 2001-948807	A1	20010907 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-465300, filed on 17 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112732P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peter L. Dolan, DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 7398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d-L.sub.n-C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a **targeting** moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L7 ANSWER 18 OF 50 USPATFULL
ACCESSION NUMBER: 2002:60966 USPATFULL
TITLE: 22105, a novel human thioredoxin family member and uses thereof
INVENTOR(S): Curtis, Rory A.J., Southborough, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002034801	A1	20020321
APPLICATION INFO.:	US 2001-801260	A1	20010306 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-187447P	20000307 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 4662
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 22105 nucleic acid molecules, which encode novel thioredoxin members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22105 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 22105 gene has been introduced or disrupted. The invention still further provides isolated 22105 proteins, fusion proteins, antigenic peptides and anti-22105 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L7 ANSWER 19 OF 50 USPATFULL
ACCESSION NUMBER: 2002:60923 USPATFULL
TITLE: Single-molecule selection methods and compositions therefrom
INVENTOR(S): Cubicciotti, Roger S., Montclair, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002034757	A1	20020321
APPLICATION INFO.:	US 2001-907385	A1	20010717 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-81930, filed on 20 May 1998, GRANTED, Pat. No. US 6287765		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
NUMBER OF CLAIMS: 129
EXEMPLARY CLAIM: 1
LINE COUNT: 15716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Single-molecule selection methods are provided for identifying **target**-binding molecules from diverse sequence and shape libraries. Complexes and imprints of selected **target**-binding molecules are also provided. The subject selection methods are used to identify oligonucleotide and nonnucleotide molecules with desirable properties for use in pharmaceuticals, drug discovery, drug delivery, diagnostics, medical devices, cosmetics, agriculture, environmental remediation, smart materials, packaging, microelectronics and nanofabrication. Single oligonucleotide molecules with desirable binding properties are selected from diverse sequence libraries and identified by amplification and sequencing. Alternatively, selected oligonucleotide molecules are identified by sequencing without amplification. Nonnucleotide molecules with desirable properties are identified by single-molecule selection from libraries of conjugated molecules or nucleotide-encoded nonnucleotide molecules. Alternatively, **target**-specific nonnucleotide molecules are prepared by imprinting selected oligonucleotide molecules into nonnucleotide molecular media. Complexes and imprints of molecules identified by single-molecule selection are shown to have broad utility as drugs, prodrugs, drug delivery systems, willfully reversible cosmetics, diagnostic reagents, sensors, transducers, actuators, adhesives, adherents and novel multimolecular devices.

L7 ANSWER 20 OF 50 USPATFULL
ACCESSION NUMBER: 2002:21796 USPATFULL
TITLE: Ternary ligand complexes useful as radiopharmaceuticals
INVENTOR(S): Liu, Shuang, Chelmsford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012631	A1	20020131
APPLICATION INFO.:	US 2001-826449	A1	20010405 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-195235P	20000407 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dupont Pharmaceuticals Company, Legal Department - Patents, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 2595
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel highly functionalized phosphine ligands as ancillary ligands in radiopharmaceuticals. Also, this invention provides radiopharmaceuticals comprised of highly functionalized phosphine ligated .sup.99mTc labeled HYNIC-conjugated biomolecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. The invention also provides methods of use of the radiopharmaceuticals as **imaging agents** for the diagnosis of **cardiovascular** disorders such as thromboembolic disease or atherosclerosis, infectious disease and cancer.

L7 ANSWER 21 OF 50 USPATFULL
ACCESSION NUMBER: 2002:3593 USPATFULL
TITLE: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS
INVENTOR(S): RAJOPADHYE, MILIND, WESTFORD, MA, UNITED STATES
EDWARDS, D. SCOTT, BURLINGTON, MA, UNITED STATES
HARRIS, THOMAS D., SAMEL, NH, UNITED STATES
HAMINWAY, STUART J., LOWELL, MA, UNITED STATES
LIU, SHUANG, CHELMSFORD, MA, UNITED STATES
SINGH, PRAHLAD R., ARLINGTON, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002001566	A1	20020103
APPLICATION INFO.:	US 1999-281474	A1	19990330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80150P	19980331 (60)
	US 1998-112715P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID H. VANCE, DUPONT PHARMACEUTICALS COMPANY, C/O E. I. DU PONT DE NEMOURS AND CO., LEGAL - PATENTS-1007 MARKET STREET, WILMINGTON, DE, 19898
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
LINE COUNT: 5872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a **targeting** moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L7 ANSWER 22 OF 50 USPATFULL
ACCESSION NUMBER: 2002:143940 USPATFULL
TITLE: Cancer treatment methods using antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406693	B1	20020618
APPLICATION INFO.:	US 1999-351543		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110608P	19981202 (60)
	US 1998-92672P	19980713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

L7 ANSWER 23 OF 50 USPATFULL
ACCESSION NUMBER: 2002:137146 USPATFULL
TITLE: Antibodies to neutrokine-alpha
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403770	B1	20020611
APPLICATION INFO.:	US 2000-589287		20000608 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000 Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999 Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176015P	20000114 (60)
	US 1999-171626P	19991223 (60)
	US 1999-171108P	19991216 (60)
	US 1999-168624P	19991203 (60)
	US 1999-167239P	19991124 (60)
	US 1999-145824P	19990727 (60)
	US 1999-142659P	19990706 (60)
	US 1999-136784P	19990528 (60)
	US 1999-131673P	19990429 (60)
	US 1999-131278P	19990427 (60)
	US 1999-130696P	19990423 (60)
	US 1999-130412P	19990416 (60)
	US 1999-127598P	19990402 (60)
	US 1999-126599P	19990326 (60)
	US 1999-124097P	19990312 (60)
	US 1999-122388P	19990302 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary L.
ASSISTANT EXAMINER: Prasad, Sarada C
LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.
NUMBER OF CLAIMS: 292
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 15430
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also

L7 ANSWER 23 OF 50 USPATFULL (Continued)
provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

L7 ANSWER 24 OF 50 USPATFULL
ACCESSION NUMBER: 2002:39639 USPATFULL
TITLE: Compounds
INVENTOR(S): Snow, Robert Allen, West Chester, PA, United States
Henrichs, Paul Mark, Houston, TX, United States
Delecki, Daniel Joseph, Radnor, PA, United States
Sanderson, William Anthony, late of Wayne, PA, United States deceasedby Audrey W. Sanderson, attorney-in-fact
Desai, Vinay Chandrakant, Phoenixville, PA, United States
Bacon, Edward, Audubon, PA, United States
Hollister, Kenneth Robert, Chester Springs, PA, United States
Hohenschuh, Eric Paul, Berwyn, PA, United States
PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, NORWAY (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350431	B1	20020226
APPLICATION INFO.:	US 1999-429347		19991028 (9)
RELATED APPLN. INFO.:	Continuation-of Ser. No. WO 1998-GB1244, filed on 29 Apr 1998 Continuation-in-part of Ser. No. US 1998-35285, filed on 5 Mar 1998, now abandoned Continuation-in-part of Ser. No. US 1997-848586, filed on 29 Apr 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-27124	19971222

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 4079
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a physiologically tolerable light imaging contrast agent compound having a molecular weight in the range 500 to 5000000 and containing at least two chromophores having delocalized electron systems as well as at least one polyalkylene oxide (PAO) moiety
having a molecular weight in the range 60 to 100000.

L7 ANSWER 25 OF 50 USPATFULL
ACCESSION NUMBER: 2001:128901 USPATFULL
TITLE: 36 human secreted proteins
INVENTOR(S): LaFleur, David W., Washington, DC, United States
Soppet, Daniel R., Centreville, VA, United States
Olsen, Henrik, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Brewer, Laurie A., St. Paul, MN, United States
Duan, Roxanne, Bethesda, MD, United States
Ebner, Reinhard, Gaithersburg, MD, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001012889	A1	20010809
APPLICATION INFO.:	US 2000-739907	A1	20001220 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-348457, filed on 7 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US108, filed on 6 Jan 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-70704P	19980107 (60)
	US 1998-70658P	19980107 (60)
	US 1998-70692P	19980107 (60)
	US 1998-70657P	19980107 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 10341
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

L7 ANSWER 26 OF 50 USPATFULL
ACCESSION NUMBER: 2001:196603 USPATFULL
TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312694	B1	20011106
APPLICATION INFO.:	US 1999-351457		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1,2,3,4
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 8243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolaminie, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-**targeted** diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

L7 ANSWER 27 OF 50 USPATFULL
ACCESSION NUMBER: 2001:179068 USPATFULL
TITLE: Heart homing peptides and methods of using same
INVENTOR(S): Ruoslahti, Erkki, Rancho Santa Fe, CA, United States
MacKenna, Deidre A., San Diego, CA, United States
PATENT ASSIGNEE(S): The Burnham Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303573	B1	20011016
APPLICATION INFO.:	US 1999-326718		19990607 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Davenport, Avis M.
LEGAL REPRESENTATIVE: Campbell & Flores LLP
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a heart homing peptide that contains the amino acid sequence GGGVPWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3); VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID NO: 10) and further provides conjugates in which a heart homing peptide is linked to a moiety such as a therapeutic agent. The conjugates of the invention are useful for treating **cardiovascular** diseases such as atherosclerosis and restenosis.

L7 ANSWER 28 OF 50 USPATFULL
ACCESSION NUMBER: 2001:152673 USPATFULL
TITLE: Methods for detecting and identifying single molecules
INVENTOR(S): Cubicciotti, Roger S., Montclair, NJ, United States
PATENT ASSIGNEE(S): Molecular Machines, Inc., Montclair, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287765	B1	20010911
APPLICATION INFO.:	US 1998-81930		19980520 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fredman, Jeffrey
LEGAL REPRESENTATIVE: Licata & Tyrrell P.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 15456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Multimolecular devices and drug delivery systems prepared from synthetic heteropolymers, heteropolymeric discrete structures, multivalent heteropolymeric hybrid structures, aptameric multimolecular devices, multivalent imprints, tethered specific recognition devices, paired specific recognition devices, nonaptameric multimolecular devices and immobilized multimolecular structures are provided, including molecular adsorbents and multimolecular adherents, adhesives, transducers, switches, sensors and delivery systems. Methods for selecting single synthetic nucleotides, shape-specific probes and specifically attractive surfaces for use in these multimolecular devices are also provided. In addition, paired nucleotide-nonnucleotide mapping libraries for transposition of selected populations of selected nonoligonucleotide molecules into selected populations of replicatable nucleotide sequences are described.

L7 ANSWER 29 OF 50 USPATFULL
ACCESSION NUMBER: 2001:97389 USPATFULL
TITLE: Ternary ligand complexes useful as radiopharmaceuticals
INVENTOR(S): Liu, Shuang, Chelmsford, MA, United States
PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251364	B1	20010626
APPLICATION INFO.:	US 1999-277936		19990329 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dudash, Diana
ASSISTANT EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Dolan, Peter L.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel radiopharmaceuticals comprised of highly functionalized pyridine ligated technetium-99m labeled HYNIC-biomolecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. The invention also provides methods of use of the radiopharmaceuticals as **imaging agents** for the diagnosis of **cardiovascular** disorders such as thromboembolic disease or atherosclerosis, infectious disease and cancer.

L7 ANSWER 30 OF 50 USPATFULL
ACCESSION NUMBER: 2001:55447 USPATFULL
TITLE: Pretargeting methods and compounds
INVENTOR(S): Meyer, Damon L., Bellevue, WA, United States
Mallett, Robert W., Seattle, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6217869	B1	20010417
APPLICATION INFO.:	US 1997-926336		19970905 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-351005, filed on 7 Dec 1994, now abandoned Continuation-in-part of Ser. No. US 163188, now abandoned Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Saunders, David
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 6397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed.

L7 ANSWER 31 OF 50 USPATFULL
ACCESSION NUMBER: 2001:29107 USPATFULL
TITLE: Stabilized microparticles and their use as ultrasound contrast agents
INVENTOR(S): Lohrmann, Rolf, La Jolla, CA, United States
Golec, Brent Lee, San Diego, CA, United States
PATENT ASSIGNEE(S): Molecular Biosystems, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6193953	B1	20010227
APPLICATION INFO.:	US 2000-521529		20000308 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-951710, filed on 16 Oct 1997, now patented, Pat. No. US 6083484 Continuation-in-part of Ser. No. US 1996-735594, filed on 17 Oct 1996, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hollinden, Gary E.
LEGAL REPRESENTATIVE: Morrison & Forrester, LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1186

AB Microparticles useful for enhancing the ultrasound image of a tissue or organ consist of liquid and/or gas core material which is encapsulated by a biocompatible, tanned protein shell. These stabilized microparticles are useful as ultrasonic **imaging agents**, and are additionally useful in the further production of functionalized microparticles for in vivo imaging. In particular, **targeting** molecules such as antibodies or other ligands can be attached to the strengthened exterior surface of the stabilized microparticles to impart **target**-specificity to the microparticles. The **targeting** molecules may also provide hydrophilicity to the exterior surface, thus increasing the recirculation time of the microparticles. The **targeting** molecules may be attached directly to the exterior surface of the microparticles, or they may be attached via a bifunctional spacer arm, which may itself be hydrophilic. The **target**-specific microparticles are injected intravenously, allowed to accumulate at the **target** site, and used to enhance the ultrasound image of a **target** tissue or organ.

L7 ANSWER 32 OF 50 USPATFULL
ACCESSION NUMBER: 2000:83825 USPATFULL
TITLE: Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents
INVENTOR(S): Lohrmann, Rolf, La Jolla, CA, United States
Golec, Brent Lee, San Diego, CA, United States
PATENT ASSIGNEE(S): Molecular Biosystems, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6083484		20000704
APPLICATION INFO.:	US 1997-951710		19971016 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-735594, filed on 17 Oct 1996, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hollinden, Gary E.
LEGAL REPRESENTATIVE: Foley & Lardner, Axford, Laurie A.
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1299

AB Microparticles useful for enhancing the ultrasound image of a tissue or organ consist of liquid and/or gas core material which is encapsulated by a biocompatible, tanned protein shell. These stabilized microparticles are useful as ultrasonic **imaging agents**, and are additionally useful in the further production of functionalized microparticles for in vivo imaging. In particular, **targeting** molecules such as antibodies or other ligands can be attached to the strengthened exterior surface of the stabilized microparticles to impart **target**-specificity to the microparticles. The **targeting** molecules may also provide hydrophilicity to the exterior surface, thus increasing the recirculation time of the microparticles. The **targeting** molecules may be attached directly to the exterior surface of the microparticles, or they may be attached via a bifunctional spacer arm, which may itself be hydrophilic. The **target**-specific microparticles are injected intravenously, allowed to accumulate at the **target** site, and used to enhance the ultrasound image of a **target** tissue or organ.

L7 ANSWER 33 OF 50 USPATFULL
ACCESSION NUMBER: 2000:7405 USPATFULL
TITLE: Stable reagents for the preparation of radio pharmaceuticals
INVENTOR(S): Sworin, Michael, 22 Appaloosa Cir., Tyngsboro, MA, United States 01879
Rajopadhye, Milind, 21 Honeysuckle Rd., Westford, MA, United States 01886
Harris, Thomas David, 56 Zion Hill Rd., Salem, NH, United States 03079
Edwards, David Scott, 123 Farms Dr., Burlington, MA, United States 01803
Cheesman, Edward Hollister, 55 Turkey Hill Rd., Lunenburg, MA, United States 01462
Liu, Shuang, 17 Judith Rd., Chelmsford, MA, United States 01864

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015904		20000118
APPLICATION INFO.:	US 1997-956313		19971023 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-476296, filed on 7 Jun 1995, now patented, Pat. No. US 5750088 which is a continuation-in-part of Ser. No. US 1994-218861, filed on 28 Mar 1994, now patented, Pat. No. US 5879657 which is a continuation-in-part of Ser. No. US 1993-40336, filed on 30 Mar 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Hartley, Michael G.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel reagents for the preparation of radiopharmaceuticals useful as **imaging agents** for the diagnosis of **cardiovascular** disorders, infection, inflammation and cancer, diagnostic kits comprising said reagents and intermediate compounds useful for the preparation of said reagents. The reagents are comprised of stable hydrazone modified biologically active molecules that react with gamma emitting radioisotopes to form radiopharmaceuticals that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy.

L7 ANSWER 34 OF 50 USPATFULL
ACCESSION NUMBER: 2000:7398 USPATFULL
TITLE: Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
Kasina, Sudhakar, Kirkland, WA, United States
Reno, John M., Brier, WA, United States
Gustavson, Linda M., Seattle, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015897		20000118
APPLICATION INFO.:	US 1996-645211		19960513 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-351005, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Seed and Berry LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 6303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. Biotinamido-N-methylglycyl-seryl-O-succinamido-benzyl DOTA is disclosed.

L7 ANSWER 35 OF 50 USPATFULL
ACCESSION NUMBER: 2000:1522 USPATFULL
TITLE: Ternary radiopharmaceutical complexes
INVENTOR(S): Edwards, David Scott, 123 Farms Dr., Burlington, MA, United States 01803
Liu, Shuang, 17 Judith Rd., Chelmsford, MA, United States 01824

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6010679		20000104
APPLICATION INFO.:	US 1998-13320		19980126 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-415908, filed on 3 Apr 1995, now patented, Pat. No. US 5744120 which is a continuation-in-part of Ser. No. US 1994-218861, filed on 28 Mar 1994, now patented, Pat. No. US 5879657 which is a continuation-in-part of Ser. No. US 1993-40336, filed on 30 Mar 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Jones, Dameron
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1664
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides novel radiopharmaceuticals which are useful as **imaging agents** for the diagnosis of **cardiovascular** disorders, infectious disease and cancer. The radiopharmaceuticals are comprised of phosphine or arsine ligated technetium-99m labeled hydrazino or diazino modified biologically active molecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. This invention also provides methods for using the radiopharmaceuticals and kits comprising radiopharmaceutical precursors. The radiopharmaceuticals of this invention have the structure:

[(Q).sub.d 'L.sub.n -C.sub.h ']. sub.x -M.sub.t (A.sub.L1).sub.y (A.sub.L2)z;

wherein the variables are as defined herein.

L7 ANSWER 36 OF 50 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:194032 CAPLUS
DOCUMENT NUMBER: 130:234067
TITLE: **Imaging agents** for early detection and monitoring of **cardiovascular plaque**
INVENTOR(S): Elmaleh, David R.; Fischman, Alan J.; Babich, John W.
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912579	A1	19990318	WO 1998-US18685	19980908
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302837	AA	19990318	CA 1998-2302837	19980908
AU 9893074	A1	19990329	AU 1998-93074	19980908
EP 1011738	A1	20000628	EP 1998-945939	19980908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1997-925213 A 19970908
WO 1998-US18685 W 19980908
AB The invention provides **imaging agents** comprising a label in assocn. with a **plaque** specific **targeting** mol.. Methods for using the **imaging agents** to diagnose or monitor **plaque** formation and growth and kits contg. the **cardiovascular** agents or components suitable for prodn. of the **imaging agents** are also provided.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 50 USPATFULL
ACCESSION NUMBER: 1999:78309 USPATFULL
TITLE: Detection and therapy of lesions with biotin/avidin-metal **chelating** protein conjugates
INVENTOR(S): Goldenberg, David Milton, Short Hills, NJ, United States
Griffiths, Gary L., Morristown, NJ, United States
Hansen, Hans J., Mystic Island, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5922302		19990713
APPLICATION INFO.:	US 1995-440652		19950515 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-409960, filed on 23 Mar 1995, now patented, Pat. No. US 5736119 which is a continuation of Ser. No. US 1993-62662, filed on 17 May 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Ponnaluri, P.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 1210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved methods of detecting and/or treating lesions in a patient are provided. The improved methods comprise the steps of (a) parenterally injecting a subject with a **targeting** composition comprised of a conjugate of biotin and **targeting** protein or of an avidin and **targeting** protein, wherein the **targeting** protein preferentially binds to a marker substance produced or associated with the **targeted** lesion, and allowing the **targeting** protein conjugate to preferentially accrete at the **targeted** lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the **targeting** composition is a biotin-**targeting** protein conjugate, or (ii) biotin, when the **targeting** composition is a avidin-**targeting** protein conjugate, and allowing the clearing composition to substantially clear the **targeting** composition from non-**targeted** sites and to bind to the **targeting** composition accreted at the **targeted** lesion; (c) parenterally injecting a localization agent which may be the same or different form the clearing agent; (d) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and naturally occurring metal-ion **chelating** protein **chelated** with **chelatable** metal detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and naturally occurring metal-ion carry protein **chelated** with **chelatable** a metal detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the **targeted** lesion. The improvement is that the use of the **chelating** protein to **chelate** a **chelatable** metal therapeutic or detection agent amplifies the amount of detection or therapeutic agent at the **targeted** site.

L7 ANSWER 37 OF 50 USPATFULL (Continued)

L7 ANSWER 38 OF 50 USPATFULL
ACCESSION NUMBER: 1999:30349 USPATFULL
TITLE: Ternary radiopharmaceutical complexes
INVENTOR(S): Edwards, David Scott, Burlington, MA, United States
Liu, Shuang, Chelmsford, MA, United States
PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5879659		19990309
APPLICATION INFO.:	US 1997-808699		19970228 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13360P	19960313 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Boudreaux, G. Jess, Vance, David H.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2121
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel radiopharmaceuticals which are useful as

imaging agents for the diagnosis of **cardiovascular** disorders, infectious disease and cancer, and to kits useful for their preparation. The radiopharmaceuticals of this invention are comprised of a transition metal **radionuclide**, a transition metal **chelator**, a biologically active group connected to said **chelator**, a first ancillary ligand, a second ancillary ligand capable of stabilizing the radiopharmaceutical, optionally having a linking group between said **chelator** and said biologically active group. Preferred radiopharmaceuticals of this invention have the formula:

[(Q).sub.d' L.sub.n --C.sub.h'].sub.x --M.sub.t (A.sub.L1).sub.y (A.sub.L2).sub.z,

wherein the shown variables are as defined herein.

L7 ANSWER 39 OF 50 USPATFULL (Continued)
polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and which are capable of binding to fibrin.

L7 ANSWER 39 OF 50 USPATFULL
ACCESSION NUMBER: 1999:19277 USPATFULL
TITLE: Fibrin binding domain polypeptides and uses and methods of producing same
INVENTOR(S): Vogel, Tikva, Rehovot, Israel
Levanon, Avigdor, Rehovot, Israel
Werber, Moshe M., Tel Aviv, Israel
Guy, Rachel, Rehovot, Israel
Panet, Amos, Jerusalem, Israel
Hartman, Jacob, Holon, Israel
Shaked, Hadassa, Ramat Gan, Israel
PATENT ASSIGNEE(S): Bio-Technology General Corp., Iselin, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869616		19990209
APPLICATION INFO.:	US 1997-826885		19970408 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-259569, filed on 14 Jun 1994, now patented, Pat. No. US 5679320, issued on 21 Oct 1997 which is a continuation of Ser. No. US 1991-703842, filed on 21 May 1991 which is a continuation-in-part of Ser. No. US 1990-526397, filed on 21 May 1990, now patented, Pat. No. US 5270030, issued on 14 Dec 1993 which is a continuation-in-part of Ser. No. US 1989-345952, filed on 28 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-291951, filed on 29 Dec 1988, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1989-2006929	19891229

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 82 Drawing Figure(s); 66 Drawing Page(s)
LINE COUNT: 3958
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides an **imaging agent** which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being

capable of binding to fibrin. The invention further provides a method wherein the **imaging agent** is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic **plaque**. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being

capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the

L7 ANSWER 40 OF 50 USPATFULL
ACCESSION NUMBER: 1998:95515 USPATFULL
TITLE: Fibrin-binding peptide fragments of fibronectin
INVENTOR(S): Gold, Leslie I., New York, NY, United States
Rostagno, Agueda A., Elmhurst, NY, United States
Baron, Martin, Oxford, United Kingdom
Campbell, Iain D., Oxford, United Kingdom
Williams, Michael J., Oxford, United Kingdom
PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)
Isis Innovation Ltd., Oxford, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5792742		19980811
APPLICATION INFO.:	US 1994-283857		19940801 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-714134, filed on 14 Jun 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 57 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 4177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fibrin-binding molecules are provided which include at least one peptide

essentially corresponding to one or both of the following portions of the natural fibronectin molecule. The first portion is that portion which includes the .sup.4 F1..sup.5 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the N-terminal

25.9 kDa proteolytic fragment. The second portion includes the .sup.10 F1..sup.11 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the C-terminal 11 kDa proteolytic fragment. Also disclosed are nucleic acid molecules encoding the fibrin-binding peptides, methods for making the peptides, methods for using the peptides in the diagnosis and treatment of **cardiovascular**, peripheral vascular, cerebrovascular, and other conditions associated with fibrin deposition, and assay methods for detecting a fibrin-binding molecule and for measuring fibrin.

L7 ANSWER 41 OF 50 USPATFULL
ACCESSION NUMBER: 1998:51174 USPATFULL
TITLE: Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
INVENTOR(S): Sworin, Michael, Tyngsboro, MA, United States
Rajopadhye, Milind, Westford, MA, United States
Harris, Thomas David, Salem, NH, United States
Edwards, David Scott, Burlington, MA, United States
Cheesman, Edward Hollister, Lunenburg, MA, United States
Liu, Shuang, Chelmsford, MA, United States
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750088		19980512
APPLICATION INFO.:	US 1995-476296		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-218861, filed on 28 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-40336, filed on 30 Mar 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hollinden, Gary E.
ASSISTANT EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Boudreaux, Gerald J., Vance, David H.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides novel reagents for the preparation of radiopharmaceuticals useful as **imaging agents** for the diagnosis of **cardiovascular** disorders, infection, inflammation and cancer, diagnostic kits comprising said reagents and intermediate compounds useful for the preparation of said reagents. The reagents are comprised of stable hydrazone modified biologically active molecules that react with gamma emitting radioisotopes to form radiopharmaceuticals that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy.

L7 ANSWER 42 OF 50 USPATFULL
ACCESSION NUMBER: 1998:44866 USPATFULL
TITLE: Ternary radiopharmaceutical complexes
INVENTOR(S): Edwards, David Scott, Burlington, MA, United States
Liu, Shuang, Chelmsford, MA, United States
PATENT ASSIGNEE(S): The DuPont Merick Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5744120		19980428
APPLICATION INFO.:	US 1995-415908		19950403 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-218861, filed on 28 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-40336, filed on 30 Mar 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kight, John
ASSISTANT EXAMINER: Jones, Dameron
LEGAL REPRESENTATIVE: Boudreaux, Gerald J., Vance, David H.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 2010
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides novel radiopharmaceuticals which are useful as **imaging agents** for the diagnosis of **cardiovascular** disorders, infectious disease and cancer. The radiopharmaceuticals are comprised of phosphine or arsine ligated technetium-99m labeled hydrazino or diazino modified biologically active molecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. This invention also provides methods for using the radiopharmaceuticals and kits comprising radiopharmaceutical precursors. The radiopharmaceuticals of this invention have the structure:

[(Q).sub.d' L.sub.n --C.sub.h'].sub.x --M.sub.t (A.sub.L1).sub.y (A.sub.L2).sub.z ;

wherein the variables are as defined herein.

L7 ANSWER 43 OF 50 USPATFULL
ACCESSION NUMBER: 1998:36340 USPATFULL
TITLE: Detection and therapy of lesions with biotin/avidin-metal **chelating** protein conjugates
INVENTOR(S): Goldenberg, David Milton, Short Hills, NJ, United States
Griffiths, Gary L., Morristown, NJ, United States
Hansen, Hans J., Mystic Island, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5736119		19980407
APPLICATION INFO.:	US 1995-409960		19950323 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-62662, filed on 17 May 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1138
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Improved methods of detecting and/or treating lesions in a patient are provided. The improved methods comprise the steps of (a) parenterally injecting a subject with a **targeting** composition comprised of a conjugate of biotin and **targeting** protein or of an avidin and **targeting** protein, wherein the **targeting** protein preferentially binds to a marker substance produced or associated with the **targeted** lesion, and allowing the **targeting** protein conjugate to preferentially accrete at the **targeted** lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the **targeting** composition is a biotin-**targeting** protein conjugate, or (ii) biotin, when the **targeting** composition is a avidin-**targeting** protein conjugate, and allowing the clearing composition to substantially clear the **targeting** composition from non-**targeted** sites and to bind to the **targeting** composition accreted at the **targeted** lesion; (c) parenterally injecting a localization agent which may be the same or different form the clearing agent; (d) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and naturally occurring metal-ion **chelating** protein **chelated** with **chelatable** metal detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and naturally occurring metal-ion carry protein **chelated** with **chelatable** a metal detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the **targeted** lesion. The improvement is that the use of the **chelating** protein to **chelate** a **chelatable** metal therapeutic or detection agent amplifies the amount of detection or therapeutic agent at the **targeted** site.

L7 ANSWER 44 OF 50 USPATFULL
ACCESSION NUMBER: 97:117899 USPATFULL
TITLE: Method of reducing immunogenicity
INVENTOR(S): Goldenberg, David M., Short Hills, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698405		19971216
APPLICATION INFO.:	US 1995-456393		19950601 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-933982, filed on 21 Aug 1992, now patented, Pat. No. US 5525338, issued on 11 Jun 1996 which is a continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827, issued on 7 Apr 1992 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210, issued on 5 Apr 1988
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spiegel, Carol A.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1093
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The immunogenicity of avidin, a therapeutic agent moiety of a conjugate, or a **targeting** composition is reduced by coupling the immunogenic agent with a carbohydrate polymer or polyol groups, such as polysaccharides (e.g. dextran), polyethylene glycol and the like.

L7 ANSWER 45 OF 50 USPATFULL
ACCESSION NUMBER: 97:96529 USPATFULL
TITLE: Fibrin binding domain polypeptides and uses and methods of producing same
INVENTOR(S): Vogel, Tikva, Rehovot, Israel
Levanon, Avigdor, Rehovot, Israel
Werber, Moshe M., Tel Aviv, Israel
Guy, Rachel, Rehovot, Israel
Panet, Amos, Jerusalem, Israel
Hartman, Jacob, Holon, Israel
Shaked, Hadassa, Ramat Gan, Israel
PATENT ASSIGNEE(S): Bio-Technology General Corp., Iselin, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5679320		19971021
APPLICATION INFO.:	US 1994-259569		19940614 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-703842, filed on 21 May 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-526397, filed on 21 May 1990, now patented, Pat. No. US 5270030, issued on 14 Dec 1993 which is a continuation-in-part of Ser. No. US 1989-345952, filed on 28 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-291951, filed on 29 Dec 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	CA 1989-2006929	19891229

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
LEGAL REPRESENTATIVE: White, John P.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 82 Drawing Figure(s); 66 Drawing Page(s)
LINE COUNT: 3888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides an **imaging agent** which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the **imaging agent** is used for imagifig a fibrin-containing substance, i.e., a thrombus or atherosclerotic **plaque**. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the

L7 ANSWER 45 OF 50 USPATFULL (Continued)
polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and which are capable of binding to fibrin.

L7 ANSWER 46 OF 50 USPATFULL
ACCESSION NUMBER: 97:44738 USPATFULL
TITLE: Detection of **cardiovascular** lesions
INVENTOR(S): Goldenberg, David M., Short Hills, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5632968		19970527
APPLICATION INFO.:	US 1994-338100		19941109 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-694977, filed on 6 May 1991, now patented, Pat. No. US 5364612

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gitomer, Ralph
ASSISTANT EXAMINER: Chapman, Lara E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 1053
AB This invention relates to reagents and methods for detecting and imaging **cardiovascular** lesions such as atherosclerotic **plaques**, vascular clots including thrombi and emboli, myocardial infarction, and other organ infarcts. Monospecific antibody **imaging agent** conjugates specific for one type of leukocyte, as well as multispecific antibody **imaging agent** conjugates specific for at least one type of leukocyte and for antigens associated with fibrin, myosin or platelets, are used in the present invention. Multispecific antibody **imaging agent** conjugates specific for at least two different antigens selected from the group consisting of fibrin-, myosin- and platelet associated antigens are also provided.

L7 ANSWER 47 OF 50 USPATFULL
ACCESSION NUMBER: 96:50642 USPATFULL
TITLE: Detection and therapy of lesions with biotin/avidin conjugates
INVENTOR(S): Goldenberg, David M., Short Hills, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5525338		19960611
APPLICATION INFO.:	US 1992-933982		19920821 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kim, Kay K. A.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 1456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for detecting and/or treating lesions in a patient. The methods use a **targeting** composition comprised of a biotin and **targeting** protein conjugate or an avidin and **targeting** protein conjugate; optionally, a clearing composition comprised of avidin, when the **targeting** composition is a biotin conjugate, or biotin, when the **targeting** composition is a avidin conjugate; a detection or therapeutic composition comprised of a conjugate of avidin or biotin with a **targeting** protein and detection or therapeutic agent; and, optionally, another detection or therapeutic composition comprised of avidin or biotin conjugated to a detection or therapeutic agent. Compositions and kits useful in the methods are also provided.

L7 ANSWER 48 OF 50 USPATFULL
ACCESSION NUMBER: 96:14715 USPATFULL
TITLE: Monocrystalline iron oxide particles for studying biological tissues
INVENTOR(S): Weissleder, Ralph, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5492814		19960220
APPLICATION INFO.:	US 1992-970942		19921103 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-725060, filed on 3 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-549434, filed on 6 Jul 1990, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Chin, Christopher L.
LEGAL REPRESENTATIVE: Fish & Richardson
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 23
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A liquid that includes monocrystalline superparamagnetic particles and a method for preparing this liquid. Also featured are a method of decreasing the NMR relaxation times of water protons in contact with biological tissue using this liquid and an in vitro method for obtaining information from biological tissue or components thereof using this liquid.

L7 ANSWER 49 OF 50 USPATFULL
ACCESSION NUMBER: 96:3496 USPATFULL
TITLE: Detection and therapy of lesions with biotin/avidin polymer conjugates
INVENTOR(S): Griffiths, Gary L., Morristown, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5482698		19960109
APPLICATION INFO.:	US 1993-51144		19930422 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wu, Shean
ASSISTANT EXAMINER: Chapman, Lara E.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 1738
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of detecting and/or treating lesions in a patient are provided. The methods are an improvement over known methods comprising the steps of (a) parenterally injecting a subject with a **targeting** composition comprised of a biotin-protein conjugate or an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the **targeted** lesion, and allowing the protein conjugate to preferentially accrete at the **targeted** lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the **targeting** composition is a biotin-protein conjugate, or (ii) biotin, when the **targeting** composition is a avidin-protein conjugate, and allowing the clearing composition to substantially clear the **targeting** composition from non-**targeted** sites and to bind to the **targeting** composition accreted at the **targeted** lesion; and (c) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the **targeted** lesion. The improvement is having at least one of the compositions of step (a) or (b) further comprise a polymer to which multiple moieties of avidin or biotin can conjugate, thereby providing an increased number of binding sites to which a subsequently administrated composition can bind thereby amplifying the amount of detection or therapeutic agent at the **targeted** site.

L7 ANSWER 50 OF 50 USPATFULL
ACCESSION NUMBER: 94:99668 USPATFULL
TITLE: Detection of **cardiovascular** lesions
INVENTOR(S): Goldenberg, David M., Short Hills, NJ, United States
PATENT ASSIGNEE(S): Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5364612		19941115
APPLICATION INFO.:	US 1991-694977		19910506 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stoll, Robert L.
ASSISTANT EXAMINER: Covert, John M.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
LINE COUNT: 1163
AB This invention relates to reagents and methods for detecting and imaging **cardiovascular** lesions such as atherosclerotic **plaques**, vascular clots including thrombi and emboli, myocardial infarction, and other organ infarcts. Monospecific antibody **imaging agent** conjugates specific for one type of leukocyte, as well as multispecific antibody **imaging agent** conjugates specific for at least one type of leukocyte and for antigens associated with fibrin, myosin or platelets, are used in the present invention. Multispecific antibody **imaging agent** conjugates specific for at least two different antigens selected from the group consisting of fibrin-, myosin- and platelet associated antigens are also provided.